Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioLineRx Ltd. (BLRX : NSDQ)

• Company Description    Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $4.88 Daily Weekly Monthly 20 Day Moving Average: 68,313 shares Shares Outstanding: 4.26 (millions) Market Capitalization: $20.80 (millions) Beta: 1.25 52 Week High: $35.60 52 Week Low: $2.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.75% -11.20% 12 Week 69.44% 42.53% Year To Date -42.99% -46.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HAMA-AYAN STREET MODI-IN TECHNOLOGY PARK - MODI-IN,L3 7177871 ISR ph: 972-2548-9100 fax: 972-8642-9101 ir@biolinerx.com http://www.biolinerx.com

• General Corporate Information    Officers Philip A. Serlin - Chief Executive Officer Aharon Schwartz - Chairman Mali Zeevi - Chief Financial Officer Raphael Hofstein - Director B.J. Bormann - Director Peer Information BioLineRx Ltd. (GSAC) BioLineRx Ltd. (CASI) BioLineRx Ltd. (ALCD.) BioLineRx Ltd. (OMNN) BioLineRx Ltd. (CGPI.) BioLineRx Ltd. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 09071M304 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/21/25 Share - Related Items Shares Outstanding: 4.26 Most Recent Split Date: 1.00 (0.03:1) Beta: 1.25 Market Capitalization: $20.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/21/25

• Fundamental Ratios P/E Current FY Estimate: 61.00 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.78 Price/Cash Flow: - Price / Sales: 0.93 EPS Growth vs. Year Ago Period: 447.50% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -96.28% vs. Previous Quarter: -97.83% ROE 06/30/25 - - 03/31/25 - -23.93 12/31/24 - -75.26 ROA 06/30/25 - - 03/31/25 - -6.80 12/31/24 - -17.75 Current Ratio 06/30/25 - - 03/31/25 - 2.27 12/31/24 - 1.76 Quick Ratio 06/30/25 - - 03/31/25 - 2.04 12/31/24 - 1.56 Operating Margin 06/30/25 - - 03/31/25 - -15.21 12/31/24 - -31.86 Net Margin 06/30/25 - - 03/31/25 - -15.21 12/31/24 - -31.86 Pre-Tax Margin 06/30/25 - - 03/31/25 - -15.21 12/31/24 - -31.86 Book Value 06/30/25 - - 03/31/25 - 6.27 12/31/24 - 4.04 Inventory Turnover 06/30/25 - - 03/31/25 - 2.30 12/31/24 - 2.80 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.37 12/31/24 - 0.67 Debt-to-Capital 06/30/25 - - 03/31/25 - 26.79 12/31/24 - 39.96

Powered by Zacks Investment Research ©